Positive Phase III data for Lupin's trichomoniasis candidate

5 May 2020

India’s Lupin (BSE: 500257) has announced positive top-line results from its pivotal Phase III clinical trial to assess efficacy and safety of single-dose Solosec (secnidazole) 2g oral granules in 147 female patients with trichomoniasis.

Solosec came into Lupin’s portfolio via its October 2017 acquisition of Symbiomix Therapeutics for around $200 million, and the drug gained US Food and Drug Administration for the treatment of bacterial vaginosis (BV) in adult women in May that year.

The trial demonstrated a clinically- and statistically-significant response rate, or microbiological cure, in patients dosed with Solosec as compared to placebo (p<0.001), with the news sending Lupin’s shares up 2.57 to 862.70 rupees yesterday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK